Log-in / Create Account  
Session Information
2007 BIO International Convention
Click here to go to the previous page
Bugs to Drugs: The Next Generation of Antiviral Therapeutics
Track : Global Health
Program Code: GLO040
Date: Monday, May 7, 2007
Time: 2:00 PM to 3:30 PM  
Location: 205 A
CHAIR :
Michael King, Senior Biotechnology Analyst, Rodman & Renshaw, LLC
SPEAKER (S):
Dr. George Painter, PhD, President & CEO, Chimerix, Inc.
Akshay Vaishnaw, Vice President of Clinical Research, Alnylam Pharmaceuticals
Peter Mueller, PhD, Chief Science Office and Executive Vice President, Drug Innovation and Realization, Vertex Pharmaceuticals, Inc.
Jennifer Hannesschlager, Senior Science Advisor, McKenna Long & Aldrich
Description
With a growing repertoire of multi-drug-resistant viruses, new classes of antiviral therapeutics needed. This panel will discuss the challenges inherent with developing therapeutics that target viral diseases and what unique and innovative strategies are being employed to develop the next-generation of antiviral compounds.



Objectives:
  • Discuss the challenges that biotechnology companies face in developing effective antiviral therapeutics.

  • Explore the potential to develop antiviral drugs that are "curative" rather than compounds that inhibit viral replication.

  • Identify and highlight novel and innovative strategies being employed to meet the growing need for next-generation antiviral therapeutics that are safe and efficacious.

    • Streaming Audio with
    PowerPoint Slides
    (Code: GLO040)
      
    This session is a part of:
    Global Health 3-DAY TRACK
    Complete Set of BIO Online / CD-ROM - All 23 Tracks.